Global Growth Companies With High Insider Ownership For April 2025

In This Article:

As global markets navigate a landscape marked by trade uncertainties and mixed performances across major indices, investors are paying close attention to the impact of geopolitical tensions on economic growth and inflation. Amid these challenges, identifying growth companies with high insider ownership can offer insights into potential investment opportunities, as insiders often have intimate knowledge of their company’s prospects and may signal confidence in its future performance.

Top 10 Growth Companies With High Insider Ownership Globally

Name

Insider Ownership

Earnings Growth

Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)

23.3%

26%

AcrelLtd (SZSE:300286)

40%

32%

Shanghai Huace Navigation Technology (SZSE:300627)

24.7%

24.4%

Pharma Mar (BME:PHM)

11.8%

40.8%

Vow (OB:VOW)

13.1%

111.2%

Laopu Gold (SEHK:6181)

36.4%

40.2%

CD Projekt (WSE:CDR)

29.7%

37.4%

Elliptic Laboratories (OB:ELABS)

22.6%

88.2%

Nordic Halibut (OB:NOHAL)

29.7%

60.7%

Fulin Precision (SZSE:300432)

13.6%

74.7%

Click here to see the full list of 871 stocks from our Fast Growing Global Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

RemeGen

Simply Wall St Growth Rating: ★★★★★★

Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of HK$23.17 billion.

Operations: The company's revenue is primarily generated from its biopharmaceutical research, service, production, and sales activities, totaling CN¥1.72 billion.

Insider Ownership: 11.6%

RemeGen is poised for significant growth, with revenue projected to increase 23.2% annually, outpacing the Hong Kong market. Despite a current net loss of CNY 1.47 billion, its earnings are expected to grow by 60.99% per year and become profitable in three years, outperforming average market expectations. Recent strategic leadership changes and promising clinical trial results for Disitamab Vedotin highlight RemeGen's focus on innovative cancer therapies, though its share price remains highly volatile.

SEHK:9995 Earnings and Revenue Growth as at Apr 2025
SEHK:9995 Earnings and Revenue Growth as at Apr 2025

Beijing Enlight Media

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Beijing Enlight Media Co., Ltd. is involved in the investment, production, and distribution of film and television projects in China, with a market cap of CN¥57.84 billion.